SLOAN-KETTERING INST CAN RESEARCH
Recombinant Interleukin-33 Immunotherapy for Pancreatic Cancer
Recombinant Interleukin-33 Immunotherapy for Pancreatic Cancer is a funding opportunity from SLOAN-KETTERING INST CAN RESEARCH, up to 569381, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
PROJECT SUMMARY – RP3 Immunotherapies can induce durable responses in advanced cancer patients and are the most exciting new cancer treatments. However, as current immunotherapies directly reinvigorate preexisting anti-tumor T cells, they are ineffective in T cell-poor (“cold”) cancers, such as pancreatic ductal…